Previous studies have demonstrated that serum TSP2 levels may serve as a biomarker for predicting advanced fibrosis and future HCC occurrence in nonalcoholic fatty liver disease patients [15, 16, 21, 22, 23]. This evidence concerns the gene THBS2 and metabolic dysfunction-associated steatotic liver disease.